Biologics GMP Gap Diagnosis
For: Biologics manufacturers preparing for a GMP inspection or a major customer audit who need a clause-by-clause gap review against the target-market GMP first.
Goal: see the gaps and priorities first, then drive targeted remediation
- Gap list and priorities against target-market GMP (21 CFR 210/211, EU GMP, PIC/S PE 009)
- Review of sterility assurance and CCS critical control points
- Data integrity (ALCOA+) current-state assessment
- Remediation roadmap and inspection-readiness document list

